Sam S. Chang MD, MBA, discusses intravesical mitomycin in low-grade intermediate-risk nonmuscle-invasive bladder cancer vs ...

[1] Safety and efficacy of bipolar versus monopolar transurethral resection of bladder tumor: a systematic review and meta-analysis. World Journal of Urology (2020).

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The Food and Drug Administration (FDA) has approved Zusduri (mitomycin intravesical solution) for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC).

A breakthrough in bladder cancer treatment at the University of California, Davis: multifunctional nanoparticles enhance ...

More than 2 centuries ago, Philipp Bozzini invented the Lichtleiter, allowing urologists to visualize what is inside the bladder. 1 About 1 century ago, Maximilian Stern invented the first ...

The U.S. Food and Drug Administration on Thursday approved UroGen Pharma's drug to treat a type of bladder cancer, providing an alternative treatment as opposed to traditional surgical procedures. U.S ...

A mucoadhesive nanoplatform improves bladder cancer imaging by selectively targeting tumors and enhancing visualization for more precise non-invasive diagnosis.

TYRA-300 is the only orally administered investigational agent in clinical development for IR NMIBC- -Initial 3-month complete response (CR) data expected to be reported ...

The FDA approved mitomycin intravesical solution (Zusduri) as a nonsurgical option for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC). The product won the indication ...

Eleven patients aged younger than 18 years were enrolled in the study. In all the patients, a bladder tumor was diagnosed using ultrasonography and was treated through transurethral resection of the ...